Intriguingly, targeting MEK/ERK pathway using MEK inhibitor trametinib induced prosurvival autophagy by activating the LKB1/AMPK/ULK1 axis in KRAS-mutated pancreatic ductal adenocarcinoma [131]. This evidence concerns the gene MAP2K7 and pancreatic ductal adenocarcinoma.